Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage

• Published in: British journal of haematology Vol. 97; no. 1; pp. 46 - 55
• Main Authors: Rawstron, Andrew C., Owen, Roger G., Davies, Faith E., Johnson, Roderick J., Jones, Richard A., Richards, Stephen J., Evans, Paul A., Child, J. Anthony, Smith, Graeme M., Jack, Andrew S., Morgan, Gareth J.
• Format: Journal Article
• Language: English
• Published: Oxford, U.K. and Cambridge, USA Blackwell Science Ltd 01.04.1997; Blackwell
• Subjects: Adult; Aged; Aged, 80 and over; Biological and medical sciences; Bone Marrow - pathology; circulating plasma cells; Female; Flow Cytometry; Gene Rearrangement, B-Lymphocyte; Humans; IgH‐PCR; Immunodeficiencies. Immunoglobulinopathies; Immunoglobulinopathies; Immunopathology; Immunophenotyping; Male; Medical sciences; Middle Aged; multiple myeloma; Multiple Myeloma - blood; Neoplasm Staging; Plasma Cells - pathology; Polymerase Chain Reaction; Stem Cells; Human; Immunopathology; Flow cytometry; Heavy peptide chain; Immunoglobulins; Malignant hemopathy; Plasmocyte; Myeloma; Polymerase chain reaction; Clinical stage; Immunoglobulinopathy; Lymphoproliferative syndrome; Molecular biology
• ISSN: 0007-1048; 1365-2141
• DOI: 10.1046/j.1365-2141.1997.72653.x

The aim of this study was to develop a flow cytometric test to quantitate low levels of circulating myeloma plasma cells, and to determine the relationship of these cells with disease stage. Cells were characterized using five‐parameter flow cytometric analysis with a panel of antibodies, and results were evaluated by comparison with fluorescent consensus‐primer IgH‐PCR. Bone marrow myeloma plasma cells, defined by high CD38 and Syndecan‐1 expression, did not express CD10, 23, 30, 34 or 45RO, and demonstrated weak expression of CD37 and CD45. 65% of patients had CD19−56+ plasma cells, 30% CD19−56low, and 5% CD19+56+, and these two antigens discriminated myeloma from normal plasma cells, which were all CD19+56low. Peripheral blood myeloma plasma cells had the same composite phenotype, but expressed significantly lower levels of CD56 and Syndecan‐1, and were detected in 75% (38/51) of patients at presentation, 92% (11/12) of patients in relapse, and 40% (4/10) of stem cell harvests. Circulating plasma cells were not detectable in patients in CR (n=9) or normals (n=10), at a sensitivity of up to 1 in 10 000 cells. There was good correlation between the flow cytometric test and IgH‐PCR results: myeloma plasma cells were detectable by flow cytometry in all PCR positive samples, and samples with no detectable myeloma plasma cells were PCR negative. Absolute numbers decreased in patients responding to treatment, remained elevated in patients with refractory disease, and increased in patients undergoing relapse. We conclude that flow cytometry can provide an effective aternative to IgH‐PCR that will allow quantitative assessment of low levels of residual disease.